Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06962059 · ClinicalTrials.gov registry record

Healthy Volunteers Study

A clinical trial of Ovarian Cancer and Genetic Predisposition to Disease, sponsored by Abramson Cancer Center at Penn Medicine.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT06962059 is a study of Ovarian Cancer and Genetic Predisposition to Disease that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 50 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06962059, a study of Ovarian Cancer and Genetic Predisposition to Disease, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the role of the bacterial environments and metabolites in the early detection and prediction of ovarian cancer development. Vaginal swabs and stool samples will be collected from healthy volunteers, or those without a known ovarian cancer diagnosis or genetic ovarian cancer risk. These samples will be compared to samples from participants with increased cancer risk and ovarian cancer diagnoses.

Interventions

  • OTHER Self-Administered Sample Collection

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-04-21
Est. Completion 2027-05-25

What the Registry Record Tells You About NCT06962059

The ClinicalTrials.gov registry entry for NCT06962059 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Self-Administered Sample Collection is the first listed.

NCT06962059 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06962059 about?

NCT06962059 is a clinical study titled "Healthy Volunteers Study". The purpose of this study is to examine the role of the bacterial environments and metabolites in the early detection and prediction of ovarian cancer development. Vaginal swabs and stool samples will be collected from healthy volunteers, or those without a known ovarian cancer diagnosis or genetic ...

What is the current status of trial NCT06962059?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-04-21. Estimated completion is 2027-05-25.

What conditions does trial NCT06962059 study?

This clinical trial studies the following conditions: Ovarian Cancer, Genetic Predisposition to Disease.

What interventions are being tested in trial NCT06962059?

The interventions under investigation include: Self-Administered Sample Collection (OTHER).

Who is sponsoring clinical trial NCT06962059?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06962059 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.